^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sutetinib (SZMD4)

    i
    Company:
    Jiangsu Suzhong Pharma, Medolution, Teligene
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (NCT06010329)
    Phase 2
    Teligene US
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    12/27/2023
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    EGFR
    |
    EGFR mutation
    |
    sutetinib (SZMD4)
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05168566)
    Phase 2b
    Teligene US
    Recruiting
    Last update posted :
    05/22/2023
    Initiation :
    09/01/2022
    Primary completion :
    08/01/2024
    Completion :
    02/01/2025
    EGFR
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    sutetinib (SZMD4)